Biomedical Engineering Reference
In-Depth Information
23. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL. (2007)
Soluble Fc fusion proteins for biomedical research. Methods
Mol. Biol. 378, 33-52.
24. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Monomeric
Fc fusions: impact on pharmacokinetic and biological activity
of protein therapeutics. BioDrugs 20, 151-160.
25. Sallusto F, Cella M, Danieli C, Lanzavecchia A. (1995)
Dendritic cells use macropinocytosis and the mannose receptor
to concentrate macromolecules in the major histocompatibility
complex class II compartment: downregulation by cytokines
and bacterial products. J. Exp. Med. 182, 389-400.
26. Gillies S. (2006) Reducing the immunogenicity of fusion
proteins. USPTO, U.P. Office, ed. (US).
27. Wolbink GJ, Aarden LA, Dijkmans BA. (2009) Dealing with
immunogenicity of biologicals: assessment and clinical rele-
vance. Curr. Opin. Rheumatol. 21, 211-215.
28. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. (2004) Eval-
uation of methods to detect and characterize antibodies against
recombinant human erythropoietin. Nephron Clin. Pract. 96,
c88-c95.
29. Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA,
Weaver JM, et al. (2005) The kinetic stability of MHC class II:
peptide complexes is a key parameter that dictates immuno-
dominance. Immunity 23, 29-40.
30. Van Regenmortel MH. (2009) What
39. De Groot AS, Martin W. (2003) From immunome to vaccine:
epitope mapping and vaccine design tools. Novartis Found.
Symp. 254, 57-72; discussion 72-76, 98-101, 250-252.
40. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM,
Gonzalez MA, et al. (2001) From genome to vaccine: in silico
predictions, ex vivo verification. Vaccine 19, 4385-4395.
41. De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD.
(2009) Immunoinformatic comparison of T-cell epitopes con-
tained in novel swine-origin influenza A (H1N1) virus with
epitopes in 2008-2009 conventional influenza vaccine. Vac-
cine 27, 5740-5747.
42. Inaba H, Martin W, De Groot AS, Qin S, De Groot LJ. (2006)
Thyrotropin receptor epitopes and their relation to histo-
compatibility leukocyte antigen-DR molecules in Graves'
disease. J. Clin. Endocrinol. Metab. 91, 2286-2294.
43. De Groot AS, Moise L. (2007) Prediction of immunogenicity
for therapeutic proteins: state of the art. Curr. Opin. Drug
Discov. Devel. 10, 332-340.
44. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin
U, et al. (1999) Generation of tissue-specific and promiscuous
HLA ligand databases using DNA microarrays and virtual
HLA class II matrices. Nat. Biotechnol. 17, 555-561.
45. Koita OA, Dabitao D, Mahamadou I, Tall M, Dao S, Tounkara
A, et al. (2006) Confirmation of immunogenic consensus
sequence HIV-1 T-cell epitopes in Bamako, Mali and Provi-
dence, Rhode Island. Hum. Vaccin. 2, 119-128.
46. Bond KB, Sriwanthana B, Hodge TW, De Groot AS, Mastro
TD, Young NL, et al. (2001) An HLA-directed molecular and
bioinformatics approach identifies new HLA-A11 HIV-1 sub-
type E cytotoxic T lymphocyte epitopes in HIV-1-infected
Thais. AIDS Res. Hum. Retroviruses 17, 703-717.
47. Dong Y, Demaria S, Sun X, Santori FR, Jesdale BM, De Groot
AS, et al. (2004) HLA-A2-restricted CD8
þ
-cytotoxic-T-cell
responses to novel epitopes in Mycobacterium tuberculosis
superoxide dismutase, alanine dehydrogenase, and glutamine
synthetase. Infect. Immun. 72, 2412-2415.
48. McMurry J, Sbai H, Gennaro ML, Carter EJ, Martin W, De
Groot AS. (2005) Analyzing Mycobacterium tuberculosis
proteomes for candidate vaccine epitopes. Tuberculosis
(Edinb.) 85, 95-105.
49. Cohen T, Moise L, Ardito M, Martin W, De Groot AS. (2010)
A method for individualizing the prediction of immunoge-
nicity of protein vaccines and biologic therapeutics: individ-
ualized T cell epitope measure (iTEM). J. Biomed.
Biotechnol. 2010; 2010: 961752. Published online 2010
July 18. doi: 10.1155/2010/961752.
50. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB,
et al. (2010) VennVax, a DNA-prime, peptide-boost multi-
T-cell epitope poxvirus vaccine, induces protective immunity
against vaccinia infection by T cell response alone. Vaccine.
2011; 29:501-511.
51. Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ,
Moxness MS. (2007) Development of a maturing T-cell-
mediated immune response in patients with idiopathic
Parkinson's disease receiving r-metHuGDNF via continuous
intraputaminal infusion. J. Clin. Immunol. 27, 620-627.
is a B-cell epitope?
Methods Mol. Biol. 524, 3-20.
31. Roggen EL. (2006) Recent developments with B-cell epitope
identification for predictive studies. J. Immunotoxicol. 3,
137-149.
32. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E,
Hoffman S, et al. (1998) Several common HLA-DR types share
largely overlapping peptide binding repertoires. J. Immunol.
160, 3363-3373.
33. Kim Y, Sette A, Peters B. (2010) Applications for T-cell
epitope queries and tools in the immune epitope database
and analysis resource. J. Immunol. Methods. 2011; 374:62-69.
34. Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles C,
et al. (1989) Prediction of major histocompatibility com-
plex binding regions of protein antigens by sequence
pattern analysis. Proc. Natl. Acad. Sci. USA 86, 3296-
3300.
35. Zhang GL, Petrovsky N, Kwoh CK, August JT, Brusic V.
(2006) PRED(TAP): a system for prediction of peptide binding
to the human transporter associated with antigen processing.
Immunome Res.2,3.
36. De Groot AS, Rayner J, Martin W. (2003) Modelling the
immunogenicity of therapeutic proteins using T cell epitope
mapping. Dev. Biol. (Basel) 112, 71-80.
37. Ahlers JD, Belyakov IM, Thomas EK, Berzofsky JA. (2001)
High-affinity T helper epitope induces complementary helper
and APC polarization, increased CTL, and protection against
viral infection. J. Clin. Invest. 108, 1677-1685.
38. De Groot AS, Rivera DS, McMurry JA, Buus S, Martin W.
(2008) Identification of immunogenic HLA-B7 “Achilles'
heel” epitopes within highly conserved regions of HIV. Vac-
cine 26, 3059-3071.
Search WWH ::
Custom Search